NexImmune (NEXI) Stock Price, News & Analysis

Company Overview

NexImmune, Inc. is a clinical-stage biotechnology company focused on developing antigen-specific immune tolerance therapies for autoimmune and inflammatory diseases. The company’s proprietary artificial antigen-presenting cell (aAPC) platform is designed to selectively modulate immune responses by expanding regulatory T cells or deleting pathogenic T cells without the need for broad immunosuppression.

The company’s lead product candidate, NX-13, is in Phase 1 clinical development for inflammatory bowel disease. In parallel, NexImmune is advancing a diversified pipeline of preclinical programs targeting conditions such as type 1 diabetes, celiac disease and transplant rejection. Early-stage studies have demonstrated promising safety profiles and on-target activity for several of these investigational therapies.

Founded in 2013 as a spinout from the La Jolla Institute for Allergy & Immunology, NexImmune is headquartered in Gaithersburg, Maryland. The company completed its initial public offering on the Nasdaq Stock Market under the ticker symbol NEXI in 2015. Its facilities support both discovery research and the manufacturing of cell therapy materials for clinical trials.

NexImmune collaborates with academic institutions and contract research organizations across North America and Europe to advance its clinical development programs. The company is led by a management team with deep expertise in immunology, cell therapy development and biotechnology commercialization.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.00 to $0.10
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 6,478 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NEXI Stock Analysis - Frequently Asked Questions

How were NexImmune's earnings last quarter?

NexImmune, Inc. (NASDAQ:NEXI) released its quarterly earnings results on Friday, November, 12th. The company reported ($16.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($16.75) by $0.50.

When did NexImmune's stock split?

Shares of NexImmune reverse split before market open on Thursday, October 19th 2023.The 1-25 reverse split was announced on Wednesday, October 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did NexImmune IPO?

NexImmune (NEXI) raised $75 million in an initial public offering on Friday, February 12th 2021. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Barclays, Cantor, Raymond James and Allen & Co. acted as the underwriters for the IPO.

How do I buy shares of NexImmune?

Shares of NEXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NexImmune own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NexImmune investors own include Athenex (ATNX), Achilles Therapeutics (ACHL), TherapeuticsMD (TXMD), Bolt Biotherapeutics (BOLT), KLX Energy Services (KLXE), Lannett (LCI) and Exela Technologies (XELA).

Company Calendar

• Last Earnings: 11/12/2021
• Today: 7/20/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NEXI
• CIK: 1538210
• Web: www.neximmune.com
• Phone: 301-825-9810
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($18.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$32.34 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -534.32%
• Return on Assets: -213.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.66
• Quick Ratio: 0.66

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.32 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,395,000
• Free Float: 1,187,000
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 1.94